Warehousing, Storage and Distribution Duties of Australian Sponsors

1. Key takeaways

During the period in which devices are under the sponsor’s control, two statutory duties are hard requirements: storage and transport in accordance with the manufacturer’s instructions and the information supplied with the device (regulation 5.9); and establishing and keeping distribution records (regulation 5.10). Retention is set in two tiers: 10 years for Class III devices, Class IIb implantable devices and Class 4 IVDs, and 5 years for everything else.

• Storage and transport must follow the manufacturer’s instructions and accompanying information.
• Distribution records extend to every individual device, not merely to batches.
• Retention runs 10 years for Class III, Class IIb implantable and Class 4 IVD devices, and 5 years otherwise.
• The Secretary can attach traceability conditions under section 41FO(2)(c).
• Specific devices still require the 20 working days advance notification of regulation 5.12.

Because the duties attach to the period in which the device is under the sponsor’s control, they begin at the point of import or supply and run until the device leaves the sponsor’s chain. Everything that happens in between — receiving, storing, picking, shipping — sits inside the regulatory perimeter.

2. Legal basis

The provisions below sit almost entirely in the device regulations, with one Act-based condition power and one practical estimate on warehousing licences. State and territory requirements sit outside this article, but sponsors should map them early, because warehouse selection is a physical decision that is expensive to reverse.

1. Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883):
2. Regulation 5.9 — during the period in which the device is under the sponsor’s control, it must be stored and transported in accordance with the manufacturer’s instructions and the information supplied with it.
3. Regulation 5.10(1)(b) — distribution records must be established as soon as practicable after distribution; regulation 5.10(2) — Class 4 IVDs, Class III devices and Class IIb implantable devices are retained for 10 years, others for 5 years (counted from the date the last product was distributed).
4. Regulation 5.12 — specific devices (Class 3 / 4 IVDs, in-house IVDs, self-test and near-patient testing IVDs, and spinal fusion implants) must be notified 20 working days before the intended import, supply or export.
5. Regulation 5.13 — devices containing poisons must not be supplied in breach of the current Poisons Standard.
6. Additional conditions: Therapeutic Goods Act 1989, section 41FO(2)(c) — the Secretary may attach conditions requiring the keeping of records enabling devices to be traced and located after supply.
7. [practical estimate] No basis was found in Commonwealth therapeutic goods law for a “warehousing licence”; warehousing and poisons storage requirements mostly fall under state or territory law.

3. Expert insights

Insight 1: distribution records must go down to every individual device. Regulation 5.10 requires distribution records for every individual device, not batch-level records. For implantable devices and Class 4 IVDs this means a serial-number-level traceability system, not a shipping list. For high-volume consumables this pushes the record system into the warehouse management software itself, so that each scan at dispatch writes the distribution record automatically instead of relying on back-office transcription.

Insight 2: the 10-year tier turns on device class, not company size. Class III devices, Class IIb implantable devices and Class 4 IVDs all carry the 10-year tier. The same company may run a 10-year and a 5-year retention regime side by side, which requires layered management. The cleanest implementation is a single retention field per product family, set at classification time and inherited by every record, so that expiry dates never depend on manual judgement.

Insight 3: attached conditions can add traceability requirements. Section 41FO(2)(c) allows the Secretary to attach a duty to keep records for tracing and locating devices after supply. This is a case-specific strong regulatory tool; it must be checked at the time the entry is approved. Where such a condition exists, the tracking ledger should be tested with a mock recall, because a condition that cannot be demonstrated in an audit is a liability rather than a safeguard.

A final structural remark. The control-period duties are deliberately narrow: they govern storage and transport while the device is in the sponsor’s hands, and they stop when the device leaves that chain. Distributors and hospitals therefore carry their own storage duties outside this framework, which makes the sponsor’s contractual flow-down of manufacturer instructions the only practical bridge between the two regimes. Without that flow-down, the sponsor complies fully at its own dock and has no visibility of what happens after.

Operationally, this makes the distribution agreement the second key document after the sponsor-manufacturer agreement. It should require downstream parties to acknowledge the manufacturer’s storage conditions, to report excursions, and to return or quarantine product that has left the prescribed conditions, so that the sponsor’s control-period duties are matched by enforceable duties further down the chain.

With those documents in place, the remaining work is verification: sampling warehouse records against the distribution ledger, checking that expiry flags in the system match the physical stock rotation, and confirming that the two retention regimes are actually producing records at the right depth for their respective classes.

4. Practical recommendations

• Build a distribution record template that reaches the unique device identification level (serial number or batch).
• Run two retention regimes — 10 years and 5 years — segmented by device class, with expiry dates flagged in the system.
• Take the temperature, humidity and handling requirements for storage and transport directly from the manufacturer’s instructions, turn them into SOPs and keep the records, reviewed whenever the manufacturer revises its labelling or instructions.
• Check whether the entry carries a traceability condition under section 41FO(2)(c); where it does, maintain a separate tracking ledger.

5. Verification checklist

• □ Storage and transport SOPs quote the manufacturer’s instructions directly
• □ Distribution records reach the unique device identification level
• □ Two retention regimes of 10 years and 5 years are segmented by class
• □ Entries have been checked for section 41FO(2)(c) traceability conditions
• □ Devices containing poisons have been checked against the Poisons Standard

Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team coordinates Australian sponsor arrangements, ARTG annual charges, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com